---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000107"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:31:14.867408+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiora receives Nasdaq deficiency notice for stock below $1.00

## Summary
- Bid price closed below $1.00 for 30 consecutive business days as of July 18, 2023.
- Company has 180 calendar days, until January 15, 2024, to regain compliance.
- To cure, closing bid price must be at least $1.00 for 10 consecutive trading days.
- If not cured, Kiora may be eligible for a second 180-day period if other listing standards are met.
- Company is evaluating options but cannot assure compliance or continued listing.

## SEC filing metadata
- accession: 0001372514-23-000107
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000107/0001372514-23-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000107/kprx-20230718.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000107
- JSON: https://secwatch.observer/filing/0001372514-23-000107.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000107.txt

## Key facts
- Listing & Compliance Notices
  KIORA PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: July 18, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000107/0001372514-23-000107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.